Sign inJoin waitlistJoin the waitlist

Christopher Willett

Mark W. Dewhirst Distinguished Professor of Radiation Oncology · Duke University Hospital

Credentials: · · · · ·

History

Duke University Hospital
Present

Radiation Oncology
Mass General Brigham
1982–1986
Preliminary General Surgery
Vanderbilt University Medical Center
1981–1982
Tufts University School of Medicine
1977–1981

Research

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Nature Medicine · 2004 · First of 23 authors · Corresponding · 1,546 citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 1,452 citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 1,286 citations

Brian Czito
83 papers · 1 as a resident
Al Benson
36 papers
Manisha Palta
32 papers · 5 as a resident
Mary Mulcahy
32 papers
PS
Paul Shellito
28 papers
David Ryan
26 papers
Jaffer Ajani
24 papers
Alan Venook
22 papers
HC
Harry Cooper
22 papers
JS
John Skibber
22 papers
CS
Constantinos Sofocleous
21 papers
David Shibata
21 papers

Grants

Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $1.1M · Duke University
2010–2014
Angiogenic Profile of Rectal Cancer
National Cancer Institute · R21
Contact PI · $526.3K · Duke University
2003–2008

Clinical trials

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2002